Compare SK Hynix (SKHY) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance

SKHY trades at $157.06, down 3.15% amid a sector-wide tech selloff driven by Fed rate hike concerns and competitive threats from Chinese chipmaker CXMT. The stock shows strong fundamentals with a P/E of 9.27, net income margin of 85.62%, and consistent earnings beats. Technical indicators are bearish with moving averages signaling selling pressure, though oscillators suggest potential oversold conditions. Recent news highlights AI memory demand growth but also increased competition risks.

Despite near-term volatility, SKHY maintains robust profitability and analyst consensus remains bullish with a $242 price target representing 54% upside. Key risks include Chinese competition and macroeconomic pressures, but the company's leadership in AI memory and strong financial metrics support long-term growth potential for patient investors.

Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.

The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.